207 related articles for article (PubMed ID: 31076632)
1. Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget's disease.
Wong SW; Huang BW; Hu X; Ho Kim E; Kolb JP; Padilla RJ; Xue P; Wang L; Oguin TH; Miguez PA; Tseng HC; Ko CC; Martinez J
Cell Death Differ; 2020 Jan; 27(1):71-84. PubMed ID: 31076632
[TBL] [Abstract][Full Text] [Related]
2. Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-κB and Interferon Signaling: Implications for Paget's Disease.
Obaid R; Wani SE; Azfer A; Hurd T; Jones R; Cohen P; Ralston SH; Albagha OME
Cell Rep; 2015 Nov; 13(6):1096-1102. PubMed ID: 26527009
[TBL] [Abstract][Full Text] [Related]
3. Optineurin regulates osteoblast function in an age-dependent fashion in a mouse model of Paget's disease of bone.
Hu X; Foster BL; Zhao B; Tseng HC; Wu YC; Ko CC
Bone; 2023 Dec; 177():116929. PubMed ID: 37802379
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of optineurin enhances osteoclast differentiation by attenuating the NRF2-mediated antioxidant response.
Xue P; Hu X; Chang E; Wang L; Chen M; Wu TH; Lee DJ; Foster BL; Tseng HC; Ko CC
Exp Mol Med; 2021 Apr; 53(4):667-680. PubMed ID: 33864025
[TBL] [Abstract][Full Text] [Related]
5. A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis.
Lu B; Jiao Y; Wang Y; Dong J; Wei M; Cui B; Sun Y; Wang L; Zhang B; Chen Z; Zhao Y
Exp Mol Med; 2017 May; 49(5):e336. PubMed ID: 28524179
[TBL] [Abstract][Full Text] [Related]
6. Optineurin regulates osteoblastogenesis through STAT1.
Mizuno N; Iwata T; Ohsawa R; Ouhara K; Matsuda S; Kajiya M; Matsuda Y; Kume K; Tada Y; Morino H; Yoshimoto T; Ueki Y; Mihara K; Sotomaru Y; Takeda K; Munenaga S; Fujita T; Kawaguchi H; Shiba H; Kawakami H; Kurihara H
Biochem Biophys Res Commun; 2020 May; 525(4):889-894. PubMed ID: 32171527
[TBL] [Abstract][Full Text] [Related]
7. Molecular effect of an OPTN common variant associated to Paget's disease of bone.
Silva IAL; Conceição N; Gagnon É; Brown JP; Cancela ML; Michou L
PLoS One; 2018; 13(5):e0197543. PubMed ID: 29782529
[TBL] [Abstract][Full Text] [Related]
8. p62/sequestosome 1 deficiency accelerates osteoclastogenesis
Zach F; Polzer F; Mueller A; Gessner A
J Biol Chem; 2018 Jun; 293(24):9530-9541. PubMed ID: 29555685
[TBL] [Abstract][Full Text] [Related]
9. Aged G Protein-Coupled Receptor Kinase 3 (Grk3)-Deficient Mice Exhibit Enhanced Osteoclastogenesis and Develop Bone Lesions Analogous to Human Paget's Disease of Bone.
Rabjohns EM; Rampersad RR; Ghosh A; Hurst K; Eudy AM; Brozowski JM; Lee HH; Ren Y; Mirando A; Gladman J; Bowser JL; Berg K; Wani S; Ralston SH; Hilton MJ; Tarrant TK
Cells; 2023 Mar; 12(7):. PubMed ID: 37048054
[TBL] [Abstract][Full Text] [Related]
10. Optineurin regulates NRF2-mediated antioxidant response in a mouse model of Paget's disease of bone.
Hu X; Wong SW; Liang K; Wu TH; Wang S; Wang L; Liu J; Yamauchi M; Foster BL; Ting JP; Zhao B; Tseng HC; Ko CC
Sci Adv; 2023 Jan; 9(4):eade6998. PubMed ID: 36706179
[TBL] [Abstract][Full Text] [Related]
11. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.
Hiruma Y; Kurihara N; Subler MA; Zhou H; Boykin CS; Zhang H; Ishizuka S; Dempster DW; Roodman GD; Windle JJ
Hum Mol Genet; 2008 Dec; 17(23):3708-19. PubMed ID: 18765443
[TBL] [Abstract][Full Text] [Related]
12. Osteoclast signaling-targeting miR-146a-3p and miR-155-5p are downregulated in Paget's disease of bone.
Stephens E; Roy M; Bisson M; Nguyen HD; Scott MS; Boire G; Bouchard L; Roux S
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165852. PubMed ID: 32485219
[TBL] [Abstract][Full Text] [Related]
13. NFAM1 signaling enhances osteoclast formation and bone resorption activity in Paget's disease of bone.
Sambandam Y; Sundaram K; Saigusa T; Balasubramanian S; Reddy SV
Bone; 2017 Aug; 101():236-244. PubMed ID: 28506889
[TBL] [Abstract][Full Text] [Related]
14. Effect of genetic variants of OPTN in the pathophysiology of Paget's disease of bone.
Silva IAL; Conceição N; Gagnon É; Caiado H; Brown JP; Gianfrancesco F; Michou L; Cancela ML
Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):143-151. PubMed ID: 28993189
[TBL] [Abstract][Full Text] [Related]
15. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice.
Daroszewska A; van 't Hof RJ; Rojas JA; Layfield R; Landao-Basonga E; Rose L; Rose K; Ralston SH
Hum Mol Genet; 2011 Jul; 20(14):2734-44. PubMed ID: 21515589
[TBL] [Abstract][Full Text] [Related]
16. Paget's Disease of Bone: Osteoimmunology and Osteoclast Pathology.
Rabjohns EM; Hurst K; Ghosh A; Cuellar MC; Rampersad RR; Tarrant TK
Curr Allergy Asthma Rep; 2021 Mar; 21(4):23. PubMed ID: 33768371
[TBL] [Abstract][Full Text] [Related]
17. The Paget's disease of bone risk gene PML is a negative regulator of osteoclast differentiation and bone resorption.
Wani S; Daroszewska A; Salter DM; van 't Hof RJ; Ralston SH; Albagha OME
Dis Model Mech; 2022 Apr; 15(4):. PubMed ID: 35229101
[TBL] [Abstract][Full Text] [Related]
18. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype.
Rea SL; Walsh JP; Ward L; Yip K; Ward BK; Kent GN; Steer JH; Xu J; Ratajczak T
J Bone Miner Res; 2006 Jul; 21(7):1136-45. PubMed ID: 16813535
[TBL] [Abstract][Full Text] [Related]
19. Genetics of Paget's disease of bone.
Ralston SH; Albagha OM
Curr Osteoporos Rep; 2014 Sep; 12(3):263-71. PubMed ID: 24988994
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62
Daroszewska A; Rose L; Sarsam N; Charlesworth G; Prior A; Rose K; Ralston SH; van 't Hof RJ
Dis Model Mech; 2018 Aug; 11(9):. PubMed ID: 30154079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
